YU49094B - Postupak za dobijanje sinergističke terapeutske kompozicije - Google Patents

Postupak za dobijanje sinergističke terapeutske kompozicije

Info

Publication number
YU49094B
YU49094B YU81991A YU81991A YU49094B YU 49094 B YU49094 B YU 49094B YU 81991 A YU81991 A YU 81991A YU 81991 A YU81991 A YU 81991A YU 49094 B YU49094 B YU 49094B
Authority
YU
Yugoslavia
Prior art keywords
synenergetic
obtaining
therapeutic composition
angiotensin
antagonist
Prior art date
Application number
YU81991A
Other languages
English (en)
Other versions
YU81991A (sh
Inventor
Anthony Andrea Fossa
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24080550&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=YU49094(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of YU81991A publication Critical patent/YU81991A/sh
Publication of YU49094B publication Critical patent/YU49094B/sh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Postupak za dobijanje sinergističke kompozicije, naznačen time, što obuhvata mešanje najmanje dva sredstva odabrana iz grupe koju sačinjavaju: a) inhibitor renina; b) inhibitor enzima koji konvertuje angiotenzin I; c) antagonist angiotenzina II. Prijava sadrži još 7 zavisnih zahteva.
YU81991A 1990-05-11 1991-05-10 Postupak za dobijanje sinergističke terapeutske kompozicije YU49094B (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US52236090A 1990-05-11 1990-05-11

Publications (2)

Publication Number Publication Date
YU81991A YU81991A (sh) 1994-06-24
YU49094B true YU49094B (sh) 2003-12-31

Family

ID=24080550

Family Applications (1)

Application Number Title Priority Date Filing Date
YU81991A YU49094B (sh) 1990-05-11 1991-05-10 Postupak za dobijanje sinergističke terapeutske kompozicije

Country Status (34)

Country Link
US (2) US6716875B1 (sh)
EP (1) EP0527879B1 (sh)
JP (2) JPH0729938B2 (sh)
KR (1) KR970005839B1 (sh)
CN (7) CN100358578C (sh)
AP (1) AP240A (sh)
AT (1) ATE148632T1 (sh)
AU (1) AU653724B2 (sh)
BG (1) BG61831B1 (sh)
BR (1) BR9106438A (sh)
CA (1) CA2081564C (sh)
DE (1) DE69124598T2 (sh)
DK (1) DK0527879T3 (sh)
EG (1) EG19648A (sh)
ES (1) ES2097208T3 (sh)
GR (1) GR3022997T3 (sh)
GT (1) GT199100032A (sh)
HK (1) HK1094148A1 (sh)
HU (1) HU227346B1 (sh)
IE (1) IE911592A1 (sh)
IL (1) IL98055A (sh)
IS (1) IS2042B (sh)
MA (1) MA22150A1 (sh)
MY (1) MY114347A (sh)
NO (1) NO924321L (sh)
NZ (1) NZ238118A (sh)
PE (1) PE30891A1 (sh)
PT (1) PT97615B (sh)
RO (1) RO115786B1 (sh)
RU (1) RU2147875C1 (sh)
TW (1) TW203553B (sh)
WO (1) WO1991017771A1 (sh)
YU (1) YU49094B (sh)
ZA (1) ZA913539B (sh)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2081564C (en) * 1990-05-11 1998-02-03 Anthony Andrea Fossa Synergistic therapeutic compositions and methods
EP0629408A1 (en) * 1993-06-16 1994-12-21 LABORATOIRES MERCK, SHARP & DOHME-CHIBRET Combination of angiotensin converting enzyme inhibitors and AII antagonists
DE4340437C1 (de) * 1993-11-27 1995-05-24 Karla Dr Lehmann Verwendung von Lithiumverbindungen zur Behandlung von Herzinsuffizienz einschließlich ihrer Folgeerkrankungen
MX9707683A (es) * 1995-04-07 1997-12-31 Novartis Ag Composiciones de combinacion que contienen benazepril o benazeprilat y valsartan.
EP0835106A4 (en) * 1995-06-30 1998-09-30 Merck & Co Inc METHOD FOR TREATING KIDNEY DISEASES USING AN ACE INHIBITOR AND AII ANTAGONIST
DE69713890T3 (de) * 1996-04-05 2006-09-07 Takeda Pharmaceutical Co. Ltd. Pharmazeutische kombination enthaltend einen wirkstoff mit angiotensin-ii antagonistischer aktivität und einen wirkstoff der die insulin-sensitivität erhöht
ES2175437T3 (es) * 1996-06-24 2002-11-16 Merck & Co Inc Composicion de enalapril y losartan.
US6087386A (en) * 1996-06-24 2000-07-11 Merck & Co., Inc. Composition of enalapril and losartan
AU9509798A (en) 1997-09-25 1999-04-12 University Of Florida Antisense oligonucleotide compositions targeted to angiotensi n converting enzy me mrna and methods of use
PT1047450E (pt) * 1997-12-23 2003-02-28 Warner Lambert Co Combinacoes inibidor ace - inibidor mmp
US6087343A (en) * 1998-09-14 2000-07-11 University Of Florida Antisense oligonucleotides targeted to β-1 adrenoceptor and methods of use
US6387894B1 (en) * 1999-06-11 2002-05-14 Pfizer Inc. Use of CRF antagonists and renin-angiotensin system inhibitors
US8168616B1 (en) * 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
WO2004002549A1 (en) * 2002-06-28 2004-01-08 Novartis Ag Use of organic compounds
PL2368553T3 (pl) 2003-04-08 2015-05-29 Progenics Pharm Inc Preparaty farmaceutyczne zawierające metylonaltrekson
US20040265238A1 (en) 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
ES2384637T3 (es) * 2004-10-08 2012-07-10 Novartis Ag Uso de inhibidores de la renina para la prevención o el tratamiento de disfunción diastólica o insuficiencia cardiaca diastólica
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
JP5241484B2 (ja) * 2005-03-07 2013-07-17 ザ ユニヴァーシティー オヴ シカゴ 内皮細胞増殖及び内皮細胞遊走を減弱するためのオピオイドアンタゴニストの使用
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
TW200817048A (en) * 2006-09-08 2008-04-16 Wyeth Corp Dry powder compound formulations and uses thereof
CL2007002689A1 (es) 2006-09-18 2008-04-18 Vitae Pharmaceuticals Inc Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.
BRPI0809579B8 (pt) 2007-03-29 2021-05-25 Progenics Pharm Inc formas cristalinas e seus usos
MX2009010552A (es) 2007-03-29 2009-12-14 Progenics Pharm Inc Antagonistas de receptor de opioide periferico y usos de los mismos.
JP5469593B2 (ja) 2007-03-29 2014-04-16 ワイス・エルエルシー 末梢性オピオイド受容体アンタゴニストおよびその使用
US8471022B2 (en) 2008-02-06 2013-06-25 Progenics Pharmaceuticals, Inc. Preparation and use of (R),(R)-2,2′-bis-methylnaltrexone
JP5647098B2 (ja) 2008-03-21 2014-12-24 ザ ユニヴァーシティー オヴ シカゴ オピオイド拮抗薬とｍＴＯＲ阻害薬を用いた治療
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
AR077692A1 (es) 2009-08-06 2011-09-14 Vitae Pharmaceuticals Inc Sales de 2-((r)-(3-clorofenil) ((r)-1-((s) -2-(metilamino)-3-((r)-tetrahidro-2h-piran-3-il) propilcarbamoil) piperidin -3-il) metoxi) etilcarbamato de metilo
CN102423483A (zh) * 2011-11-24 2012-04-25 西北农林科技大学 一种复方雷米普利纳米乳抗高血压药物
CN114032273B (zh) * 2021-11-17 2024-02-02 山东省科学院生物研究所 一种多功能西洋参水解肽及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US324377A (en) * 1885-08-18 Roller-skate
US4046889A (en) * 1976-02-13 1977-09-06 E. R. Squibb & Sons, Inc. Azetidine-2-carboxylic acid derivatives
IL58849A (en) * 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
JPS5671074A (en) * 1979-11-12 1981-06-13 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
US4749688A (en) 1986-06-20 1988-06-07 Schering Corporation Use of neutral metalloendopeptidase inhibitors in the treatment of hypertension
CA1334092C (en) 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
US4814342A (en) 1986-10-31 1989-03-21 Pfizer Inc. Nor-statine and nor-cyclostatine polypeptides
US4895834A (en) * 1986-12-15 1990-01-23 Warner-Lambert Company Renin inhibitors III
US4962105A (en) 1987-10-19 1990-10-09 Ciba-Geigy Corporation Potentiation of antihypertensive effect of ace inhibitors
CA1338238C (en) * 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
US4880804A (en) * 1988-01-07 1989-11-14 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking benzimidazoles
US5015651A (en) 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
IL91780A (en) 1988-10-04 1995-08-31 Abbott Lab History of the amine of the xenon-preventing xanine acid, the process for their preparation and the pharmaceutical preparations containing them
CA2081564C (en) * 1990-05-11 1998-02-03 Anthony Andrea Fossa Synergistic therapeutic compositions and methods

Also Published As

Publication number Publication date
PT97615B (pt) 1998-08-31
ZA913539B (en) 1992-12-30
IE911592A1 (en) 1991-11-20
HU9203522D0 (en) 1993-01-28
YU81991A (sh) 1994-06-24
JPH0729938B2 (ja) 1995-04-05
KR970005839B1 (ko) 1997-04-21
JPH0748280A (ja) 1995-02-21
DE69124598T2 (de) 1997-05-28
NZ238118A (en) 1997-06-24
CN1502370A (zh) 2004-06-09
CN1824315B (zh) 2011-01-12
PE30891A1 (es) 1991-11-27
JPH05505618A (ja) 1993-08-19
BG61831B1 (bg) 1998-07-31
RO115786B1 (ro) 2000-06-30
ES2097208T3 (es) 1997-04-01
AP9100258A0 (en) 1991-07-31
WO1991017771A1 (en) 1991-11-28
MY114347A (en) 2002-10-31
AU7859191A (en) 1991-12-10
MA22150A1 (fr) 1991-12-31
ATE148632T1 (de) 1997-02-15
US6716875B1 (en) 2004-04-06
BG97068A (bg) 1993-12-24
CN1307901A (zh) 2001-08-15
TW203553B (sh) 1993-04-11
IS3703A7 (is) 1991-11-12
CN1879884A (zh) 2006-12-20
HUT62804A (en) 1993-06-28
BR9106438A (pt) 1993-05-18
CA2081564C (en) 1998-02-03
CN1824315A (zh) 2006-08-30
EP0527879B1 (en) 1997-02-05
IL98055A (en) 1996-10-31
NO924321D0 (no) 1992-11-10
US6900234B1 (en) 2005-05-31
GR3022997T3 (en) 1997-07-30
CN100358578C (zh) 2008-01-02
HK1094148A1 (en) 2007-03-23
IL98055A0 (en) 1992-06-21
IS2042B (is) 2005-09-15
JP2635291B2 (ja) 1997-07-30
HU227346B1 (en) 2011-04-28
DK0527879T3 (da) 1997-07-14
CN1056426A (zh) 1991-11-27
GT199100032A (es) 1992-10-31
CN101156949A (zh) 2008-04-09
DE69124598D1 (de) 1997-03-20
EP0527879A1 (en) 1993-02-24
EG19648A (en) 1995-09-30
RU2147875C1 (ru) 2000-04-27
PT97615A (pt) 1992-03-31
AU653724B2 (en) 1994-10-13
CN1065140C (zh) 2001-05-02
AP240A (en) 1993-02-18
CN1915428A (zh) 2007-02-21
CA2081564A1 (en) 1991-11-12
NO924321L (no) 1993-01-08

Similar Documents

Publication Publication Date Title
YU49094B (sh) Postupak za dobijanje sinergističke terapeutske kompozicije
ATE148130T1 (de) Typ-iv-dipeptidyl-aminopeptidase-inhibitoren
ES2170252T3 (es) Tetrahidroimidazopiridoindoldionas como inhibidores de cgmp especifico pde.
SE9504661D0 (sv) New compounds
EA199700186A1 (ru) Новые дипептидные амидины, используемые в качестве ингибиторов тромбина
TR199800077T1 (xx) Kontroll� ��z�len paroksetin terkipleri.
ATE247470T1 (de) Neue substituierte imidazolverbindungen
PT772603E (pt) Compostos substituidos de pirimidina e sua utilizacao
DK0531410T3 (da) (+)-alfa-(2,3-Demethoxyphenyl)-1-(2-(4-fluorphenyl)ethyl)-4-piperidinmethanol
PT935465E (pt) Compostos novos de imidazole substituido
CL2003002756A1 (es) Compuestos derivados de (1-carbamoil-1,1-defenilmetil)-1-[substituido)alquil]purrolidinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del sindrome de intestino irritable o incontinencia.
YU48528B (sh) Analozi 5-(1-hidroksi-2-piperidinopropil)-2-(1h,3h)-indolona
DE69427704D1 (de) Neue (r)-5-carbamoyl-8-fluor-3-n,n-disubstituierte-amino-3,4-dihydro-2h-1-benzopyrane
NO960630L (no) Heterocykler anvendelige som neurokinin antagonister
ATE260658T1 (de) Pharmazeutische zubereitungen zur verminderung von atmungsdepressionen
ATE193647T1 (de) Di- und trivalente kleine moleküle als selektininhibitoren
MY111055A (en) Pharmaceutical composition and process for the preparation thereof
BR9809848A (pt) Composição
ES2088128T3 (es) Aminosulfonilureas inhibidoras de acat.
ATE229800T1 (de) Guanidino proteiase inhibitoren
TR199800243T1 (xx) Prolil endopeptidaz inhibit�rleri.
DK0696278T3 (da) Herbicidtvirkende substituerede 1-phenyl- eller 1-pyridinylbenzotriazoler
DK0823909T3 (da) Hidtil ukendte heterocykliske forbindelser
SE9504662D0 (sv) New compounds
ES2136615T3 (es) Nuevos inhibidores de glucohidrolasa utiles como agentes antidiabeticos, antiviricos y antimetastasicos.